Member Info for technick

Dodge, if there is anything material such as sales or regulatory approvals this will be announced, they have to be. Just because the Company has issued a date for the presentation does not put the Company into a radio silence. Your statement has to be an opinion that nothing material will happen, but 24 days is a long time, its therefore not a fact, simply an opinion...

I think the fall is just the uneducated market responding to the 'life back to normal buy summer' mentality so no testing required, but it fails to recognise the virus is so well distributed that mutations will more likely than not create waves of new variants, testing is not going a way. LFD not sensitive enough, molecular testing the only option, Genedrive lab and POC tests are going to come into their own shortly. We can expect the POC IVD approvals in the coming weeks, Beckman lined up to distribute that in the US perhaps too? A lot more to come here shortly, and Beckman sales...

Grim, the only proviso to this is that I have seen the test described in the formal document back to the patient if the test is done by a private provider, not the case I know in the UK but could be the case in the US. May not be clear cut

We should see a POC update this week or next week, that will be the CE-IVD approvals for sale in the EU and possible hear about an EUA for that product in the US. That will be another huge tick, particularly if Beckman are also the reseller to the market for that product too.... LTHs, this is going to be a good year for us!!

yes it does, DB not stupid, as a LTH the opportunity the company is in to trade sale exit is too big an opportunity to miss. of course time will tell

acquisition later in the year has to happen, there would be a number of interested parties, but BC/Danaher the obvious

Agree, 1 robot places would create 1k-2k bead requirement a day, £120k-£240k profit to GDR. 2 placements covers the business burn rate.

Also, installed machines can’t stop running and have no test kits to run, pretty much guaranteed income when a robot is bought and the genedrive test run on it. BC won’t just place 35 machines world wide, they’ll be placing 100s

some of us have known this since the start :D

https://www.newscientist.com/article/2268014-exclusive-two-variants-have-merged-into-heavily-mutated-coronavirus/

the reason why testing is here to stay, as fast as we can develop new vaccines, new variants will arrive that overcome these, it will be a long term test / develop / vaccinate effort over the coming years before we start to get on top of this pandemic

BC selling this at a price of $24,000 a time, 960 tests a go, an 8-hour day throughput per Biomek so $8.76m per install. This gears up massively, 10, 100, 1000 installs as the multiplier

$24,000 for 10x 96 samples - that's $24 per sample and you can only buy $24,000 a time, that should give some indication of value here! This is going to be huge. So much so I think Genedrive will end up having to pay out a hefty dividend next year if they are not acquired. Looking really good everyone!!!

LordPaul - £1.70
AC177 - £1.78
Technick - £1.90

I think it means that from mid February, following commercial and technical training of the Beckman sale and support organisations, the Companies are planning the commercial introduction of the Genedrive kit

Longtermer, but remember Cytiva are doing the manufacturing and likely the logistics to supply Beckman, at these scales it would not make sense to use GDR as the centre for distribution.... Cytiva already distribute world wide, I think DB is a genius in the way this has been constructed. Patience indeed, but the cogs are in place to churn these efficiently

At £3m--£4m profit for Genedrive with each Biomek installed to run GDR tests, it won't be long before its obvious that the current market cap doesn't reflect the sales volumes, also the fact the covid will be here for many years with variants and a vaccine that doesn't stop spread and therefore the emergence of new variants, the testing opportunity will become consistent sales on which to multiple 5x to get to a market cap.

Do the math, 100 units is £400m in profit, 5x multiple?

Testing has to be, probably even more, since vaccination doesn't mean you don't carry or pass it on... just have fewer symptoms, its a therapy not a cure...

Hey BigAl, who ever its buying so that's a good thing! Possibly and RNS after hours or later in the week, certainly next week I think we should hear something. Maybe FDA EUA granted? News from so many directions to come!

I'm not convinced its II buying as they would simply buy direct from calculus or BGF rather than in the open market, this likely non-II but anyone with a view?

Let's put some perspective on the opportunity.

If only 1 Biomek was sold and ran at capacity it would process 730,000 tests per year with 2 shifts, giving Genedrive £4.38m in profit ! That is just 1....!!

Beckman are not going to place just 1 system in the US and EU. How many? 10, 100?

The gearing is phenomenal here